Highest-materiality recent filing
Axogen Q2 revenue $69.7M (+23% YoY), raises FY2026 guidance to at least $279M (24% growth)
Revenue $69.7M, up 23.1% YoY; net loss $1.5M ($0.03/sh) vs net income $0.6M ($0.01/sh) in Q2 2025.
Axogen shareholders elect eight directors, ratify auditors, approve say-on-pay
All eight director nominees elected with 97.3%-99.6% votes for; Paul Thomas 39,087,824 for.
Axogen Q1 revenue $61.5M (+27% YoY); raises FY 2026 revenue guidance to at least $270M
Q1 revenue $61.5M, up 26.6% YoY; gross margin expanded to 75.2% from 71.9%.
Axogen Q4 revenue $59.9M (+21%); FY2025 $225.2M; guides 2026 growth >=18%
Q4 revenue $59.9M (+21.3% YoY); net loss $13.2M ($0.28/sh); adjusted net income $3.5M ($0.07/sh).
Axogen prices $124M public offering at $31/share; proceeds to pay off $69.7M credit facility
Pricing of upsized 4M share offering at $31.00/share for gross proceeds of ~$124M (assuming no over-allotment).
Q4 2025 revenue ~$59.9M (+21.3% YoY); full-year 2025 revenue ~$225.2M (+20.2% YoY).
Axogen raises CFO Hartley's base salary 7%, bonus target to 60%, adds 2-year non-compete
CFO Lindsey Hartley's annual base salary increased by 7% effective January 1, 2026.
Axogen receives FDA approval of BLA for Avance nerve allograft under Accelerated Approval pathway
FDA approved Biologics License Application for Avance (acellular nerve allograft) for sensory, mixed, motor nerve discontinuities in adults and pediatric patients 1 month+.
Axogen Q3 revenue $60.1M (+23.5% YoY); raises FY revenue guidance to at least $222.8M
Net income of $0.7M ($0.01 EPS) vs net loss of $1.9M in Q3 2024; adjusted EPS $0.12 vs $0.07.
FDA extends PDUFA date for Axogen's Avance Nerve Graft BLA to Dec 5, 2025
FDA deemed Axogen's August 22 submission a Major Amendment, extending PDUFA goal date by three months to Dec 5, 2025.
Axogen Q2 2025 revenue $56.7M (+18.3% YoY); raises FY guidance to $219M
Q2 revenue $56.7M (+18.3% YoY); net income $0.6M ($0.01 EPS) vs loss of $1.9M ($0.04) year ago.
Axogen shareholders approve all five proposals at 2025 annual meeting
Elected eight directors to one-year terms; all received >26.7M votes for.
Axogen Q1 revenue $48.6M (+17.4% YoY); appoints Lindsey Hartley as CFO
Q1 revenue $48.6M, up 17.4% YoY; net loss $3.8M ($0.08/share) vs $6.6M loss in Q1 2024.
Axogen anticipates minimal impact from new U.S. tariffs on operations
President Trump announced broad tariff plan on April 2, 2025.
Axogen posts updated corporate presentation on investor website
Updated investor presentation dated March 4, 2025 posted to Axogen's website.
Axogen Q4 2024 revenue up 15.1% to $49.4M; reports first quarterly net income of $0.4M
Q4 revenue $49.4M (+15.1% YoY); gross margin 76.1% vs 74.6%.
Axogen reports Q4 2024 revenue $49.4M (+15.1% YoY); FY 2024 revenue $187.3M (+17.8%)
Q4 2024 revenue expected $49.4M, up 15.1% YoY; full-year 2024 revenue $187.3M, up 17.8%.
Axogen Q3 revenue $48.6M (+18% YoY), adjusted net income $3.1M; BLA accepted by FDA
Revenue $48.6M (+17.9% YoY); gross margin 74.9% vs 76.8% in prior year.
Axogen completes BLA submission to FDA for Avance Nerve Graft; priority review requested
FDA submission for Avance Nerve Graft completed under rolling review process on Sept. 6, 2024.
Axogen appoints Michael Dale as CEO; Karen Zaderej steps down, remains advisory
Michael Dale becomes CEO, President, and Director effective August 9, 2024; Karen Zaderej exits CEO role.
Axogen Q2 revenue up 25.6% to $47.9M; net loss narrows; raises FY guidance
Revenue $47.9M (+25.6% YoY); net loss $1.9M ($0.04/share) vs $6.7M loss prior year.
Axogen shareholders elect all nine directors, approve LTIP share increase to 10.5M
All nine director nominees elected; broker non-votes 4,270,312 on each proposal.
Axogen shareholders vote down proposal to increase LTIP share reserve; Freitag departs board
Gregory Freitag not re-nominated; Board accelerated vesting of 11,904 RSUs and options for 20,436 shares.
Axogen Q1 2024 revenue $41.4M (+12.9% YoY); net loss narrows to $6.6M; adj EBITDA turns positive
Revenue $41.4M, up 12.9% YoY; gross margin improved to 78.8% from 77.7%.
Axogen Chief R&D Officer Scopelianos resigns; transition consulting through Dec 2024
Angelo Scopelianos resigns as Chief R&D Officer effective no later than March 31, 2024.
Axogen reports Q4 2023 revenue $42.9M (+18.7% YoY); 2024 revenue guidance $177-181M
Q4 net loss $3.9M ($0.09/share) vs $5.4M loss in Q4 2022; adjusted EBITDA turned positive at $0.6M.
Axogen posts updated corporate presentation to website on March 5, 2024
The presentation was posted to Axogen's investor relations website for use with analysts and investors.
Axogen posts updated corporate presentation; no material changes disclosed
Company posted an updated corporate presentation to its IR website on January 5, 2024.
Axogen CFO Peter Mariani departs; receives $473K severance, $25K/month consulting
CFO Peter Mariani separated effective Dec 22, 2023; lump sum severance $472,999.54 (12 months base) plus bonus equivalent $60,437.83.
Axogen reports preliminary Q4 revenue $42.7M (+18% YoY); CEO Karen Zaderej to retire by Jan 2025
Q4 revenue $42.7M (+18% YoY); FY2023 revenue $158.8M (+15% YoY) at high end of $154-159M guidance.
Axogen appoints Kathy Weiler to its board, effective Dec 20, 2023
Board expanded to 10; Weiler serves on Governance, Nominating & Sustainability and Quality, Compliance & Portfolio committees.
Axogen appoints Nir Naor as CFO; Peter Mariani departs; FY2023 revenue guidance reaffirmed $154-159M
Nir Naor appointed CFO effective Dec 4, 2023, replacing Peter Mariani who stepped down at Board's request.
Axogen Q3 revenue $41.3M (+12% YoY); maintains FY2023 guidance $154-159M
Revenue $41.3M (+12% YoY); scheduled non-trauma grew ~20%, emergent trauma mid-single digits.
Axogen VP of Operations Mike Donovan to retire March 22, 2024; responsibilities to Todd Puckett
Mike Donovan, VP of Operations, to retire effective March 22, 2024; transition planned.
Axogen shareholders reject incentive plan share increase at 2023 annual meeting
Proposal to increase LTIP shares from 8M to 10.5M failed with 11.3M for vs 18.6M against (excluding broker non-votes).
Axogen Q2 revenue $38.2M (+11% YoY); net loss narrows to $6.7M
Revenue $38.2M in Q2 2023, up 11% vs Q2 2022; scheduled procedures grew >20%, trauma low-single-digit.
Axogen amends term loan to transition from LIBOR to Adjusted Term SOFR
Amendment No. 1 executed June 29, 2023 changes benchmark rate from LIBOR to Adjusted Term SOFR plus spread adjustment.
Axogen Q1 revenue up 18% to $36.7M; net loss narrows; FDA clears Axoguard HA+
Net revenue $36.7M (+18% YoY); net loss $7.1M vs $11.5M prior year.
Axogen sets 2023 annual meeting for Aug 15; shareholder proposals due May 11
2023 Annual Shareholders' Meeting scheduled for August 15, 2023.
Axogen reports Q4 revenue $36.2M (+17% YoY); guides FY2023 revenue $154M-$159M
Q4 revenue $36.2M, up 17% YoY; gross margin 83.0%; net loss $5.4M ($0.13/sh).
Axogen's $8M SVB deposits fully protected; moving other assets to JP Morgan
Axogen had $8M cash at SVB, its sole depositor; FDIC guarantees full access as of March 13.
Axogen reports preliminary Q4 2022 revenue of $36.1M, up 16% YoY ex-Avive; FY22 $138.5M, up 12%
Q4 revenue $36.1M, up 14% reported or 16% excluding Avive; FY22 $138.5M, up 9% reported or 12% ex-Avive.
Axogen Q3 revenue $37.0M (+18% YoY); net loss narrows to $4.3M; guidance raised
Net loss $4.3M ($0.10/sh) vs $7.1M loss ($0.17/sh) in Q3 2021; adjusted net loss $0.4M ($0.01/sh).
Axogen appoints Adrian Tyndall to board; founding director Mark Gold retires Dec 13
Founding director Dr. Mark Gold resigns effective Dec 13, 2022; no dispute cited.
Axogen expands Burleson facility and amends tissue processing agreement
First Amendment to Burleson lease doubles space to 5,000 sq ft, extends term to September 2027.
Axogen Q2 revenue $34.5M (+3% YoY); adjusted net loss narrows to $2.6M; reaffirms FY2022 guidance
Net revenue $34.5M, +3% YoY; ex-Avive (suspended June 2021) revenue grew 9%.
Axogen announces CCO departure, preliminary Q2 rev $34.4M (+2% YoY)
Eric Sandberg, Chief Commercial Officer, terminated without cause effective July 19, 2022; eligible for severance per employment agreement.
Axogen appoints William Burke to Board of Directors, effective July 11, 2022
William Burke, former EVP & CFO of Haemonetics, appointed as director effective July 11, 2022.
Axogen stockholders approve expanded LTIP, reject bylaw amendment at annual meeting
Stockholders approved Second Amended 2019 LTIP, increasing shares from 5.5M to 8.0M.
Axogen Q1 rev flat at $31M, net loss widens to $0.20/sh; Avance Phase 3 hits endpoint
Net revenue $31.0M flat YoY; adjusted net loss $8.5M ($0.20/sh) vs $3.1M ($0.08) prior year.
On May 8, 2025, Axogen, Inc. (the “Company”) announced the appointment of Lindsey Hartley as its Chief Financial Officer, effective May 12, 2025
Nir Naor, the Chief Financial Officer (the “CFO”) of the Company, will step down from his role effective May 11, 2025
On August 8, 2024, Axogen, Inc. (the “Company”), announced the appointment of Michael Dale as its Chief Executive Officer (“CEO”) and President, effective August 9, 2024 (the “Effective Date”).
Mr. Gregory Freitag was not re-nominated for re-election.
Angelo Scopelianos notified Axogen, Inc. (the “Company”) of his intention to resign as the Company’s Chief Research and Development Officer no later than March 31, 2024 (the “Separation Date”).
Mr. Mariani’s severance benefits in connection with his departure include a severance amount equal to 12 months of his current base compensation and COBRA benefits for 12 months after he ceased to be an employee of the Company on December 22, 2023 (the “Separation Date”).
Retirement of Karen Zaderej Karen Zaderej, the Chief Executive Officer (the “CEO”) and President of the Company informed the Company of her intention to retire in January 2025.
On December 20, 2023, the board of directors (the “Board”) of Axogen, Inc. (the “Company”) increased the size of the Board from nine directors to ten directors, and appointed Kathy Weiler to fill the newly created vacancy effective December 20, 2023.
Effective upon Mr. Naor’s appointment, Peter Mariani stepped down from his role as the Executive Vice President and Chief Financial Officer of the Company and Axogen Corporation, a Delaware corporation (“AC”) and wholly owned subsidiary of the Company, at the request of the Board.
On December 6, 2023, Axogen, Inc. (the “Company”) announced the appointment of Nir Naor as Chief Financial Officer, effective December 4, 2023.
On September 19, 2023, Mike Donovan, the Vice President of Operations of Axogen, Inc. (the “Company”) informed the Company of his intention to retire, effective March 22, 2024 (the “Retirement Date”).
On October 24, 2022, Mark Gold, M.D. notified Axogen, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), including as a member of the Quality, Compliance and Portfolio Management Committee, effective as of 3:00 PM EST on Tuesday, December 13, 2022.
Max materiality 0.85 · Median 0.65 · Most common event earnings